Lisdexamfetamine dimesylate: A new option in stimulant treatment for ADHD

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 17, 2010, Pages 2907-2913

  Dew, Rachel E ^a   Kollins, Scott H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ADHD; Lisdexamfetamine; Stimulant therapy

Indexed keywords

DEXAMPHETAMINE; IMIPRAMINE; LISDEXAMFETAMINE; MESYLIC ACID; METHYLPHENIDATE; MONOAMINE; OROS; PLACEBO; TRAZODONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGITATION; ALOPECIA; ANOREXIA; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE FLUCTUATION; CATECHOLAMINE UPTAKE; CLINICAL TRIAL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG LEGISLATION; DRUG SAFETY; DYSPEPSIA; DYSURIA; EUPHORIA; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEPATITIS; HUMAN; HYPERACTIVITY; HYPERKINESIA; INSOMNIA; IRRITABILITY; MORNING DOSAGE; MOTOR DYSFUNCTION; MUSCLE CRAMP; NAUSEA; NOSE CONGESTION; PRURITUS; PULSE RATE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUDDEN DEATH; THROAT IRRITATION; TINNITUS; URINARY EXCRETION; WEIGHT REDUCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; HUMANS;

EID: 78149460700     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.531009     Document Type: Review

References (39)

1. Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/ hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007;161(9):857-64
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163(4):716-23
3. Goldstein RB, Grant BF. Three-year follow-up of syndromal antisocial behavior in adults: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2009;70(9):1237-49
4. Pappadopulos E, Jensen PS, Chait AR, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 2009;48(5):501-10
5. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 2008;12(2):115-25
6. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
7. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122(1):184-91
8. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther 2008;30(5):942-57
9. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008;22(3):213-37
10. Sonuga-Barke EJ, Coghill D, Wigal T, et al. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009;19(6):683-90
11. Murray DW, Arnold LE, Swanson J, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/ hyperactivity disorder (MTA). Curr Psychiatry Rep 2008;10(5):424-31
12. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117(18):2407-23
13. Olfson M, Marcus SC, Zhang HF, Wan GJ. Continuity in methylphenidate treatment of adults with attention-deficit/ hyperactivity disorder. J Manag Care Pharm 2007;13(7):570-7
14. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004;18(14):1011-30
15. Fredericks EM, Kollins SH. Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology (Berl) 2004;175(4):391-8
16. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26(10):1501-10
17. Weisler RH. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 2007;8(6):745-58
18. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107(6):e105
19. New River Pharmaceuticals. Vyvanse product monograph. New River Pharmaceuticals, Blacksburg, VA; 2007. p. 1-6
20. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009;57(7-8):608-18
21. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig 2008;28(12):745-55
22. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62(9):970-6
23. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48(3):293-302
24. Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007;35(1):180-4
25. Ermer J, Homolka R, Martin P, et al. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010;50(9):1001-10
26. Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin Ther 2010;32(2):252-64
27. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-27
28. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009;23(4):410-18
29. Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009;3(1):17
30. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29(3):450-63
31. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008;13(7):614-20
32. Faraone SV, Spencer TJ, Kollins SH, Glatt SJ. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 2010;49(1):24-32
33. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69(9):1364-73
34. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2009;70(12):1652-61
35. Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr 2009;14(10):573-85
36. Wigal T, Brams M, Gasior M, et al.Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 2010;6:34. Available from: http:// www. behavioralandbrainfunctions.com/ content/6/1/34
37. Spiller HA, Griffith JR, Anderson DL, et al. Poison centers detect an unexpectedly frequent number of adverse drug reactions to lisdexamfetamine. Ann Pharmacother 2008;42(7):1142-3
38. Brahm NC, Hamilton DR. Alopecia following initiation of lisdexamfetamine in a pediatric patient. Prim Care Companion J Clin Psychiatry 2009;11(6):365
39. Hood B, Nowicki MJ. Eosinophilic hepatitis in an adolescentduring lisdexamfetamine dimesylate treatment for ADHD. Pediatrics 2010;125(6):e1510-13